期刊文献+

质子泵抑制剂治疗咽喉反流患者声嘶症状的疗效观察 被引量:4

The therapeutic effect of proton pump inhibitor on alleviation of hoarseness symptoms in patients with laryngopharyngeal reflux
原文传递
导出
摘要 目的:探讨质子泵抑制剂(PPI)治疗咽喉反流(LPR)患者声嘶症状的疗效。方法:60例以声嘶为主诉LPR患者,随机分为A、B两组:A组(30例)给予金嗓开音胶囊治疗(1.2g/次,2次/d,口服,连用3个月);B组(30例)在A组的基础上同时加用奥美拉唑治疗(20mg/次,2次/d,口服,连用3个月)。在治疗前和治疗后1、2、3个月分别记录以下数据:反流症状指数(RSI),反流体征指数(RFS)和嗓音障碍指数(VHI),比较A、B两组上述参数变化的差异。结果:60例患者治疗前RSI和RFS分别与VHI评分比较,均呈显著正相关(r=0.823,P<0.01;r=0.873,P<0.01)。与治疗前相比,B组治疗后1、2、3个月的RSI和VHI的评分变化显著高于A组,差异有统计学意义(P<0.01)。B组治疗后1、2个月的RFS评分与A组比较差异无统计学意义(t=1.128,P>0.05;t=0.376,P>0.05),但治疗后3个月RFS评分显著高于A组(t=8.307,P<0.01)。结论:PPI治疗可显著改善LPR患者的声嘶症状。 Objective:To analyze the therapeutic effect of proton pump inhibitor(PPI) on alleviation of hoarse- ness symptoms in patients with laryngopharyngeal reflux(LPR). Method: The LPR outpatients in ENT depart- ment of our hospital(60 cases)complained of hoarseness were enrolled in the study from August of 2013 to October of 2014. All of them were randomly divided into group A and B. The individuals in group A (30 cases) taked golden voice capsule to treat for 3 months, while the individuals in group B (30 cases) raked golden voice capsule and omeprazole to treat for 3 months. The data about reflux symptom index (RSI). reflux finding score (RFS) and voice handicap index (VHI)from the first month to the third month after treatment were recorded and compared group A with group 13. Result:The scores of RSI and RFS in patients (60 cases) before treatment were significantly correlated with their VHI (r=0.823, P〈0.01; r=0.873, P〈0. 01). The score changes of RSI and VHI from the first to the third month after treatment in group B were significantly higher than those in group A (P〈0.01). Meanwhile, the score changes of RFS from the third month after treatment in group B were significantly higher than those in group A (t=8. 307,P〈0. 01), but the differences were not significant for RFS from the first to the second month after treatment between group A and group B(t=1. 128,P〉0.05;t=0. 376,P〉0.05). Conclusion.. PPI therapy could significantly alleviate the hoarseness symptom in LPR patients.
出处 《临床耳鼻咽喉头颈外科杂志》 CAS 北大核心 2015年第11期997-1001,共5页 Journal of Clinical Otorhinolaryngology Head And Neck Surgery
关键词 声嘶 咽喉反流 质子泵抑制剂 hoarseness laryngopharyngeal reflux proton pump inhibitor
  • 相关文献

参考文献26

二级参考文献91

  • 1王晓晔,韩德民,叶京英.咽喉反流[J].国际耳鼻咽喉头颈外科杂志,2006,30(5):281-285. 被引量:46
  • 2Jacobson BH, Johnson A, Grywalski C, et al. The Voice Handicap Index ( VHI ) : development and validation. Am J Speech Lang Pathol, 1997, 6:66-70.
  • 3Lam PK, Chan KM, Ho WK, et al. Cross-cultural adaptation and validation of the Chinese Voice Handicap Index-10. Laryngoscope, 2006, 116:1192-1198.
  • 4Rosen CA, Lee AS, Osborne J, et al. Development and validation of the voice handicap index-10. Laryngoscope, 2004, 114: 1549-1556.
  • 5Hsiung MW, Lu P, Kang BH, et al. Measurement and validation of the voice handicap index in voice-disordered patients in Taiwan. J Laryngol Otol, 2003, 117:478-481.
  • 6Amir O, Ashkenazi O, Leibovitzh T, et al. Applying the Voice Handicap Index (VHI) to dysphonic and nondysphonic Hebrew speakers. J Voice, 2006, 20:318-324.
  • 7Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol, 1993,46:1417-1432.
  • 8Guimaraes I, Abberton E. An investigation of the Voice Handicap Index with speakers of Portuguese: preliminary data. J Voice, 2004, 18:71-82.
  • 9Hakkesteegt MM, Wieringa MH, Gerritsma E J, et al. Reproducibility of the Dutch version of the Voice Handicap Index. Folia Phoniatr Logop, 2006, 58 : 132-138.
  • 10Adams J, Heintz P, Gross N, et al. Acid/pepsin promotion of carcinogenesis in the hamster cheek pouch. Arch Otolaryngol Head Neck Surg, 2000, 126 : 405-409.

共引文献273

同被引文献67

  • 1李占鲁,周斌全,朱军慧,傅国胜.质子泵抑制剂和氯吡格雷联用与支架内再狭窄关系的回顾性研究[J].浙江大学学报(医学版),2011,40(6):667-672. 被引量:7
  • 2王晓晔,韩德民,叶京英.咽喉反流[J].国际耳鼻咽喉头颈外科杂志,2006,30(5):281-285. 被引量:46
  • 3王晓晔,叶京英,韩德民.全天咽喉pH检测在诊断反流性咽喉部疾病中的作用[J].中华耳鼻咽喉头颈外科杂志,2007,42(11):834-838. 被引量:40
  • 4Kyle GJ, Nissen LM ,Tett SE. The Australian rise of es- omeprazole-was expenditure on samples a contributor?[J]. Pharmacoepidemiol Drag Saf, 2009,18( 1 ) : 62-68.
  • 5Hollingworth S,Duncan EL,Martin JH. Marked increase in proton pump inhibitors use in australia[J]. Pharmacoepi- demiol Drug Saf, 2010, 19(10) : 1019-1024.
  • 6Schiller D, Maieron A, Schofl R, et al. Drug fever due to a single dose of pantoprazole[J]. Pharmacology, 2014,94 ( 1 - 2) :78-79.
  • 7Das S, Ganguly A, Ghosh A,et al. Oral pantoprazole-in- duced acute pancreatitis in an ll-year-old child[J]. Ther Drug Monit, 2012,34 (3) : 242-244.
  • 8Fracaroli TS, Miranda LQ, Sodre JL,et al. Toxic epider- mal necrolysis induced by lansoprazole[J]. An Bras Der- matol,2013,88(1) : 117-120.
  • 9Dunn SP,Steinhubl SR,Bauer D,et al. impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the caprie and credo trials[J]. J Am Heart Assoc,2013,2 ( 1 ) : e004564.
  • 10Leonard CE,Bilker WB,Brensinger CM,et al. Compara- tive risk of ischemic stroke among users of elopidogrel together with individual proton pump inhibitors[J]. Stroke, 2015,46(3) :722-731.

引证文献4

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部